Literature DB >> 3124481

B cell lymphoma showing clinicopathological features of malignant histiocytosis.

H Kuratsune1, T Machii, K Aozasa, E Ueda, Y Tokumine, T Morita, S Tagawa, N Taniguchi, R Inoue, T Kitani.   

Abstract

This report describes a case of B cell lymphoma, the clinicopathological features of which are quite similar to those of malignant histiocytosis. The clinical features included fever, anemia, and marked hepatosplenomegaly without lymphadenopathy. Histological findings revealed diffuse and noncohesive proliferation of cytologically atypical cells and benign-appearing histiocytes in the splenic red pulp, where the erythrophagocytosis was frequently found. Immunological studies, however, revealed a B cell nature of proliferating atypical cells. Accordingly, the histology of this patient was interpreted as a neoplastic proliferation of B cells accompanied by marked proliferation and activation of the histiocytes.

Entities:  

Mesh:

Year:  1988        PMID: 3124481     DOI: 10.1159/000205729

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

1.  Primary splenic diffuse large B-cell lymphoma manifesting in red pulp.

Authors:  Makoto Kashimura; Masahiro Noro; Bunshiro Akikusa; Atsushi Okuhara; Shuji Momose; Ikuo Miura; Masaru Kojima; Jun-Ichi Tamaru
Journal:  Virchows Arch       Date:  2008-09-26       Impact factor: 4.064

2.  Prevalence of intravascular large B-cell lymphoma with bone marrow involvement at initial presentation.

Authors:  Masafumi Ito; Yonggoo Kim; Jong Weon Choi; Hiroaki Ozawa; Masahiko Fujino
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.

Authors:  Tatsuharu Ohno; Yasunori Ueda; Ken-ichi Nagai; Takayuki Takahashi; Yoshiteru Konaka; Teruyuki Takamatsu; Takayo Suzuki; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.